Cardiovascular aspects of antipsychotics
- 1 November 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 23 (6) , 574-581
Abstract
Schizophrenia is associated with increased mortality and reduced life expectancy, with cardiovascular disease being the most frequent cause of death. Antipsychotics have detrimental effects on different risk factors for cardiovascular disease. This review will focus on the relationship between antipsychotic treatment and cardiovascular disease. The increased overall mortality and mortality from cardiovascular disease in schizophrenia are now well documented. Patients with schizophrenia are at risk of receiving less optimal treatment for cardiovascular disease. Patients with schizophrenia are at high risk of metabolic syndrome, a cluster of risk factors for cardiovascular disease. Some antipsychotics, in particular, clozapine and olanzapine, frequently cause weight gain, dyslipidemia and diabetes mellitus. Antipsychotics differ in their effects on body weight, lipids and glucose regulation. However, the long-term effects of these differences between individual antipsychotics on overall mortality and cardiovascular mortality are not well established. More research is needed to better understand the relationship between schizophrenia, antipsychotic treatment and cardiovascular disease. More effective treatment strategies need to be developed to reduce the burden of cardiovascular disease in schizophrenia.Keywords
This publication has 110 references indexed in Scilit:
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one yearJournal of Psychiatric Research, 2009
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who smokeGeneral Hospital Psychiatry, 2009
- Exposure to antipsychotics and risk of stroke: self controlled case series studyBMJ, 2008
- Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1Schizophrenia Research, 2008
- Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjectsSchizophrenia Research, 2008
- A Systematic Review of Mortality in SchizophreniaArchives of General Psychiatry, 2007
- Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophrenia Research, 2007
- Venous Thromboembolism Among Elderly Patients Treated With Atypical and Conventional Antipsychotic AgentsArchives of internal medicine (1960), 2005